Literature DB >> 11326242

L-arginine polymers inhibit the development of vein graft neointimal hyperplasia.

M H Kown1, A Yamaguchi, C L Jahncke, D Miniati, S Murata, J Grunenfelder, M L Koransky, J B Rothbard, R C Robbins.   

Abstract

OBJECTIVE: We sought to determine whether L -arginine polymer treatment of vein grafts enhances vascular production of nitric oxide and inhibits the development of neointimal hyperplasia.
METHODS: External jugular veins of New Zealand White rabbits (n = 42) were harvested; treated intraluminally for 15 minutes with phosphate-buffered saline solution or L -arginine polymer 5, 7, or 9 at either 10 or 100 micromol/L; and then grafted into the contralateral carotid artery. Rabbits were killed after 28 days, and 5-microm sections of vessels were stained with hematoxylin and scored for intima/media ratio by using computerized morphometric analysis. Separate veins were treated in a similar fashion with biotinylated polymers and phosphate-buffered saline solution to assess for translocation efficiencies. Finally, vein segments pretreated with either phosphate-buffered saline solution or L -arginine polymers were cultured in Dulbecco's modified Eagle's medium containing lipopolysaccharide (100 microg/mL) and interferon gamma (200 U/mL) for 48 hours before measuring nitric oxide levels by means of the Griess reaction.
RESULTS: Biotinylated L -arginine polymers demonstrated a dose- and length-dependent uptake into intimal and medial cells of treated vessels. Nitric oxide levels were significantly higher in vein segments treated with 100 micromol/L of L -arginine polymer 9 compared with control segments. Finally, the intima/media ratio also reflected both length- and concentration-dependent inhibition of neointimal hyperplasia.intima/media ratio PBS R5 R7 R9 10 micromol/L 0.909 +/- 0.072 0.920 +/- 0.073 0.861 +/- 0.138 0.710 +/- 0.122 100 micromol/L 0.924 +/- 0.061 0.581 +/- 0.089* 0.529 +/- 0.093* PBS, Phosphate-buffered saline solution; R, L -arginine polymer. *P <.001 versus phosphate-buffered saline solution and L -arginine polymer 5 controls (Bonferroni-corrected value).
CONCLUSIONS: Arginine polymers of sufficient length and concentration were effective in increasing nitric oxide levels and reducing neointimal hyperplasia in this vein graft model.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11326242     DOI: 10.1067/mtc.2001.112532

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  10 in total

1.  Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism.

Authors:  Toshio Hayashi; Teiji Esaki; Daigo Sumi; Tapan Mukherjee; Akihisa Iguchi; Gautam Chaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

2.  Role of metabolic environment on nitric oxide mediated inhibition of neointimal hyperplasia in type 1 and type 2 diabetes.

Authors:  Monica P Rodriguez; Zachary M Emond; Zheng Wang; Janet Martinez; Qun Jiang; Melina R Kibbe
Journal:  Nitric Oxide       Date:  2013-12-12       Impact factor: 4.427

3.  Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes.

Authors:  Vinit N Varu; Sadie S Ahanchi; Melissa E Hogg; Hussein A Bhikhapurwala; Amy Chen; Daniel A Popowich; Ashley K Vavra; Janet Martinez; Qun Jiang; Joseph E Saavedra; Joseph A Hrabie; Larry K Keefer; Melina R Kibbe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

4.  The role of estrogen receptor α and β in regulating vascular smooth muscle cell proliferation is based on sex.

Authors:  Melissa E Hogg; Ashley K Vavra; Monisha N Banerjee; Janet Martinez; Qun Jiang; Larry K Keefer; Pierre Chambon; Melina R Kibbe
Journal:  J Surg Res       Date:  2011-10-08       Impact factor: 2.192

5.  Identification and characterization of a novel cell-penetrating peptide.

Authors:  Jingwei Sheng; George Oyler; Bin Zhou; Kim Janda; Charles B Shoemaker
Journal:  Biochem Biophys Res Commun       Date:  2008-12-11       Impact factor: 3.575

6.  Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass.

Authors:  Semih Yucel; Muzaffer Bahcivan; Mehmet Kamil Gol; Behice H Erenler; Fersat Kolbakir; Hasan T Keceligil
Journal:  Tex Heart Inst J       Date:  2009

7.  Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia.

Authors:  Muneera R Kapadia; Lesley W Chow; Nick D Tsihlis; Sadaf S Ahanchi; Jason W Eng; Jozef Murar; Janet Martinez; Daniel A Popowich; Qun Jiang; Joseph A Hrabie; Joseph E Saavedra; Larry K Keefer; James F Hulvat; Samuel I Stupp; Melina R Kibbe
Journal:  J Vasc Surg       Date:  2008-01       Impact factor: 4.268

8.  Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia.

Authors:  Charles G Pearce; Samer F Najjar; Muneera R Kapadia; Jozef Murar; Jason Eng; Brian Lyle; Oliver O Aalami; Qun Jiang; Joseph A Hrabie; Joseph E Saavedra; Larry K Keefer; Melina R Kibbe
Journal:  Free Radic Biol Med       Date:  2007-09-25       Impact factor: 7.376

9.  Graft preservation confers myocardial protection during coronary artery bypass grafting.

Authors:  Philipp Szalkiewicz; Maximilian Y Emmert; Paul P Heinisch; Zsuzsanna Arnold; Ingo Crailsheim; Markus Mach; Thomas Aschacher; Martin Grabenwöger; Bernhard Winkler
Journal:  Front Cardiovasc Med       Date:  2022-07-28

10.  Effects of the cationic protein poly-L-arginine on airway epithelial cells in vitro.

Authors:  Shahida Shahana; Caroline Kampf; Godfried M Roomans
Journal:  Mediators Inflamm       Date:  2002-06       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.